Hi everyone as on 3rd July we are starting with ABFM Unit 9 - Capital Budgeting
❤2👍2
Hello Bankers !!!
अगर सपना है CAIIB Dec 2025 क्लियर करने का…
तो Strong Base बनाओ BFM और ABM से!
🎓 Priyanshu Ma’am के साथ करिए स्मार्ट तैयारी।
👇 👇 👇
https://www.youtube.com/watch?v=k-ENM0ya1Qg
अगर सपना है CAIIB Dec 2025 क्लियर करने का…
तो Strong Base बनाओ BFM और ABM से!
🎓 Priyanshu Ma’am के साथ करिए स्मार्ट तैयारी।
https://www.youtube.com/watch?v=k-ENM0ya1Qg
Please open Telegram to view this post
VIEW IN TELEGRAM
❤1
Hi everyone you might rec msg of reschedule of classes today as my laptop is nt working my daughter dropped water on it. It will be tomorrow
The laptop issue is now fixed class will resume today.!!!
❤1
Share the solution of MIRR homework question
❤1
Should we start with Quiz of ABFM. What do you suggest??
Waiting for Certificate .????https://www.instagram.com/p/DMU-padpYgN/?igsh=OGF2cjkzMnVqdzdo
i have extreme headache… rescheduling my class.
❤1
Forwarded from Shimpy Thakur
📌 Important Message for Bankers & DBF Aspirants!
⏰ Last Day Today!
If you wish to:
✅ Extend the validity of your JAIIB/CAIIB course
✅ Enquire about new batches for JAIIB/CAIIB preparation
✅ Prepare exclusively for any specific subject of JAIIB/CAIIB
👉 Please contact immediately at:
📞 09240231024 or 09819819247
Don't miss out—reach out today!
Team Officers ADDA247
⏰ Last Day Today!
If you wish to:
✅ Extend the validity of your JAIIB/CAIIB course
✅ Enquire about new batches for JAIIB/CAIIB preparation
✅ Prepare exclusively for any specific subject of JAIIB/CAIIB
👉 Please contact immediately at:
📞 09240231024 or 09819819247
Don't miss out—reach out today!
Team Officers ADDA247
❤4
CASE STUDY: Three-Stage Growth Valuation – Zenith Biocare Ltd.
Zenith Biocare Ltd. currently reports Earnings per Share (EPS) of ₹12. The management anticipates the following growth trajectory:
🔹 Stage 1: High-Growth Phase (Years 1–4)
EPS will grow at 30% annually for the next 4 years.
Dividend payout ratio remains constant at 20%.
Cost of equity: 18%
🔹 Stage 2: Transition Phase (Years 5–7)
EPS growth rate will decline linearly from 30% to 18% over these 3 years.
Dividend payout will increase linearly from 20% to 50%.
Cost of equity will decrease by 1% annually, starting from 18% in year 5.
🔹 Stage 3: Stable Phase (Year 8 onwards)
EPS growth stabilizes at 6% annually, indefinitely.
Dividend payout stabilizes at 60%
Cost of equity: 15%
You are required to estimate the intrinsic value of the share using the Three-Stage Dividend Discount Model.
Zenith Biocare Ltd. currently reports Earnings per Share (EPS) of ₹12. The management anticipates the following growth trajectory:
🔹 Stage 1: High-Growth Phase (Years 1–4)
EPS will grow at 30% annually for the next 4 years.
Dividend payout ratio remains constant at 20%.
Cost of equity: 18%
🔹 Stage 2: Transition Phase (Years 5–7)
EPS growth rate will decline linearly from 30% to 18% over these 3 years.
Dividend payout will increase linearly from 20% to 50%.
Cost of equity will decrease by 1% annually, starting from 18% in year 5.
🔹 Stage 3: Stable Phase (Year 8 onwards)
EPS growth stabilizes at 6% annually, indefinitely.
Dividend payout stabilizes at 60%
Cost of equity: 15%
You are required to estimate the intrinsic value of the share using the Three-Stage Dividend Discount Model.
👏5❤4